Asia Pacific Hemato Oncology Testing Market Size & Outlook
Asia Pacific hemato oncology testing market, 2018-2028 (US$M)
Related Markets
Asia Pacific hemato oncology testing market highlights
- The Asia Pacific hemato oncology testing market generated a revenue of USD 426.8 million in 2020.
- The market is expected to grow at a CAGR of 13% from 2021 to 2028.
- In terms of segment, lymphoma was the largest revenue generating cancer type in 2020.
- Lymphoma is the most lucrative cancer type segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2021 to 2028.
Asia Pacific data book summary
| Market revenue in 2020 | USD 426.8 million |
| Market revenue in 2028 | USD 1,136.2 million |
| Growth rate | 13% (CAGR from 2020 to 2028) |
| Largest segment | Lymphoma |
| Fastest growing segment | Lymphoma |
| Historical data covered | 2018 - 2019 |
| Base year for estimation | 2020 |
| Forecast period covered | 2021 - 2028 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Leukemia, Lymphoma, MPNs, Other Cancers |
| Key market players worldwide | Roche Holding AG, Abbott Laboratories, Qiagen NV, Danaher Corp, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Illumina Inc, Bio-Techne Corp |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 18.3% of the global hemato oncology testing market in 2020.
- Globally, North America is projected to lead the regional market in terms of revenue in 2028.
- North America is the fastest growing regional market and is projected to reach USD 2,516.4 million by 2028.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Hemato Oncology Testing Market Scope
Hemato Oncology Testing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific hemato oncology testing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hemato oncology testing market will help companies and investors design strategic landscapes.
Lymphoma was the largest segment with a revenue share of 46.04% in 2020. Horizon Databook has segmented the Asia Pacific hemato oncology testing market based on leukemia, lymphoma, mpns, other cancers covering the revenue growth of each sub-segment from 2018 to 2028.
Asia Pacific hemato-oncology market is expected to grow at the fastest rate during the forecast period. It is primarily driven by China, Japan, India, and Australia. Japan and China are expected to witness strong growth during the forecast period.
Recent approval & commercialization of novel tests in the countries, growing awareness & adoption of testing, supportive government regulations, and high prevalence of blood cancers are likely to drive the market over the coming years.
Furthermore, increase in investments, development of novel tests, and entry of major market players in Asia Pacific are expected to boost market growth during the forecast period.
Reasons to subscribe to Asia Pacific hemato oncology testing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific hemato oncology testing market databook
-
Our clientele includes a mix of hemato oncology testing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific hemato oncology testing market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific hemato oncology testing market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific hemato oncology testing market size, by country, 2018-2028 (US$M)
Asia Pacific Hemato Oncology Testing Market Outlook Share, 2020 & 2028 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
